European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment: Cardio-oncology quality indicators

TY - JOUR

T1 - European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment

T2 - Cardio-oncology quality indicators

AU - Lee, G A

AU - Aktaa, S

AU - Baker, E

AU - Gale, C P

AU - Israa fadhil, Yaseen

AU - Gulati, G

AU - Asteggiano, R

AU - Szmit, S

AU - Cohen-Solal, A

AU - Abdin, A

AU - Jurczak, W

AU - Garrido lopez, P

AU - Sverdlov, A L

AU - Tocchetti, C G

AU - Barac, A

AU - Parrini, I

AU - Zamorano, P

AU - Iakobishvili, Z

AU - Pudil, R

AU - Badimon, L

AU - Kirby, A M

AU - Blaes, A H

AU - Farmakis, D

AU - Curigliano, G

AU - Stephens, R

AU - Lyon, A R

AU - Lopez-Fernandez, T

N1 - Publisher Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2022/12/13

Y1 - 2022/12/13

N2 - Aims: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy.Conclusion: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

AB - Aims: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. Methods and results: We followed the European Society of Cardiology (ESC) methodology for QI development which comprises (i) identifying the key domains of care for the prevention and management of cancer therapy-related cardiovascular toxicity in patients on cancer treatment, (ii) performing a systematic review of the literature to develop candidate QIs, and (iii) selecting of the final set of QIs using a modified Delphi process. Work was undertaken in parallel with the writing of the 2022 ESC Guidelines on Cardio-Oncology and in collaboration with the European Haematology Association, the European Society for Therapeutic Radiology and Oncology and the International Cardio-Oncology Society. In total, 5 main and 9 secondary QIs were selected across five domains of care: (i) Structural framework, (ii) Baseline cardiovascular risk assessment, (iii) Cancer therapy related cardiovascular toxicity, (iv) Predictors of outcomes, and (v) Monitoring of cardiovascular complications during cancer therapy.Conclusion: We present the ESC Cardio-Oncology QIs with their development process and provide an overview of the scientific rationale for their selection. These indicators are aimed at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes.

KW - Cardio-Oncology

KW - QUALITY INDICATORS

UR - http://www.scopus.com/inward/record.url?scp=85144094283&partnerID=8YFLogxK

U2 - 10.1093/ehjqcco/qcac070

DO - 10.1093/ehjqcco/qcac070

M3 - Article

SN - 2058-5225

VL - 9

SP - 1

EP - 7

JO - European Heart Journal - Quality of Care and Clinical Outcomes

JF - European Heart Journal - Quality of Care and Clinical Outcomes

IS - 1

ER -